Click Here! Click Here!
 
Click Here!
 
 
 

 

 

Colorectal cancer
Regorafenib shows benefit in Phase III CORRECT trial

Benoît Samson, MD, Hematologist and Medical Oncologist, Hôpital Charles Lemoyne, Greenfield Park, Québec; Clinical Professor, Faculté de médecine et des sciences de la santé (FMSS), Université de Sherbrooke, Sherbrooke, Québec.

To view the complete article click here (pdf format)

 

TRIAL SUMMARY:
Regorafenib produced statistically significant benefits in OS and PFS

 

To view the complete article click here (pdf format)

 
Back to Top of Page 

 

 
 
ANNUAL MEETING OF ASCO GI CANCERS SYMPOSIUM January 19-21, 2012, San Francisco, California

IN BRIEF

Already known

  • Acquired chemoresistance may be mediated by the activation of alternate oncogenic pathways.

What this study showed

  • Regorafenib + best supportive care (BSC) produced statistically significant benefits in OS and PFS, a high rate of disease control and a relative tolerable toxicity profile vs placebo + BSC.

Next steps

  • Identification of a more responsive patient population based on predictive biomarkers may enhance the clinical benefit from treatment with regorafenib.
  • Ongoing Phase I trials are testing the safety of regorafenib + mFOLFOX6 and FOLFIRI, as well as different dosing schedules.
  • Phase II trials are currently recruiting to evaluate regorafenib + FOLFIRI in the second-line setting in patients with mCRC with KRAS–, BRAF– mutated tumours.
Click Here! Click Here!
© Parkhurst Publishing Privacy Statement
Legal Terms of Use